"The block of toxicology studies would consist of subacute and/or subchronic toxicity studies including safety pharmacology, pharmacodynamic and reproduction performance end points, stand-alone safety pharmacology studies (telemetry studies), pharmacokinetic studies. Non-clinical toxicity studies must be performed when the biological drug candidate is progressing through the clinical development (from Phase I to Phase III) i.e., chronic toxicity studies and reproduction toxicology studies (enhanced pre- and postnatal development studies in non-human primates or the classical segment II and III reproduction.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Costa SL (2014) Antiglioma Potential of Flavonoides. J Bioanal Biomed 6: e124."
Last date updated on April, 2021